Novartis’ Mayzent Receives Health Canada’s Approval for Secondary Progressive Multiple Sclerosis with Active Disease

 Novartis’ Mayzent Receives Health Canada’s Approval for Secondary Progressive Multiple Sclerosis with Active Disease

Novartis’ Mayzent Receives Health Canada’s Approval for Secondary Progressive Multiple Sclerosis with Active Disease

Shots:

  • The approval is based on P-III EXPAND study assessing Mayzent vs PBO in 1651 patients with SPMS from 31 countries including 47 participants in Canada with a mean age of 48yrs., living with MS for ~16yrs., >50% had a median EDDS score of 6.0 and relied on a walking aid
  • The P-III EXPAND study result demonstrated a reduction in diseases progression, including impact on physical disability
  • Mayzent is an S1P receptor modulator and the first oral therapy approved for SPMS with active disease. The approval of Mayzent is a tribute to Novartis’s relentless commitment to reimagining MS treatment

Click here ­to­ read full press release/ article | Ref: Novartis | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post